Simon Spazzapan

3.0k total citations
60 papers, 776 citations indexed

About

Simon Spazzapan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Simon Spazzapan has authored 60 papers receiving a total of 776 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 19 papers in Cancer Research and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Simon Spazzapan's work include Cancer Treatment and Pharmacology (25 papers), Breast Cancer Treatment Studies (16 papers) and HER2/EGFR in Cancer Research (13 papers). Simon Spazzapan is often cited by papers focused on Cancer Treatment and Pharmacology (25 papers), Breast Cancer Treatment Studies (16 papers) and HER2/EGFR in Cancer Research (13 papers). Simon Spazzapan collaborates with scholars based in Italy, Ukraine and Switzerland. Simon Spazzapan's co-authors include Diana Crivellari, Davide Lombardi, Andrea Veronesi, Loredana Militello, Elena Muraro, Debora Martorelli, Massimiliano Berretta, Simona Scalone, Renato Talamini and Marco Trovò and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Cochrane Database of Systematic Reviews.

In The Last Decade

Simon Spazzapan

56 papers receiving 759 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Simon Spazzapan Italy 16 495 246 244 91 85 60 776
Jenny Furlanetto Germany 16 553 1.1× 215 0.9× 278 1.1× 98 1.1× 66 0.8× 47 797
Jacques Camerlo France 18 448 0.9× 162 0.7× 190 0.8× 67 0.7× 49 0.6× 50 932
C. Oberhoff Germany 16 454 0.9× 234 1.0× 164 0.7× 40 0.4× 165 1.9× 45 1.1k
G. Schubert-Fritschle Germany 16 485 1.0× 217 0.9× 185 0.8× 67 0.7× 40 0.5× 58 847
Danielle Desautels Canada 10 562 1.1× 136 0.6× 152 0.6× 140 1.5× 37 0.4× 28 814
Cristina Falci Italy 17 347 0.7× 183 0.7× 104 0.4× 64 0.7× 41 0.5× 55 828
David Topolsky United States 15 348 0.7× 123 0.5× 127 0.5× 86 0.9× 59 0.7× 39 884
Camille Chakiba France 15 370 0.7× 316 1.3× 125 0.5× 57 0.6× 43 0.5× 35 798
Dimitri Korol Switzerland 16 322 0.7× 162 0.7× 115 0.5× 103 1.1× 59 0.7× 42 742
Eleonora Pagan Italy 17 343 0.7× 192 0.8× 232 1.0× 69 0.8× 54 0.6× 48 936

Countries citing papers authored by Simon Spazzapan

Since Specialization
Citations

This map shows the geographic impact of Simon Spazzapan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Spazzapan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Spazzapan more than expected).

Fields of papers citing papers by Simon Spazzapan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Spazzapan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Spazzapan. The network helps show where Simon Spazzapan may publish in the future.

Co-authorship network of co-authors of Simon Spazzapan

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Spazzapan. A scholar is included among the top collaborators of Simon Spazzapan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Spazzapan. Simon Spazzapan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Lisanti, C., Anna Costantini, Mattia Garutti, et al.. (2023). 458P Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey. Annals of Oncology. 34. S373–S374.
4.
Polesel, Jerry, et al.. (2023). Mild Cryotherapy for Prevention of Paclitaxel-Induced Nail Toxicity in Breast Cancer Patients: A Phase II Single-Arm Clinical Trial. Clinical Breast Cancer. 23(4). 447–453. 2 indexed citations
5.
Kovač, Milena, Tina Pavlin, Domen Ribnikar, et al.. (2023). The trajectory of sarcopenia following diagnosis of prostate cancer: A systematic review and meta-analysis. Journal of Geriatric Oncology. 14(7). 101594–101594. 7 indexed citations
6.
Muraro, Elena, Mariangela De Zorzi, Gianmaria Miolo, et al.. (2022). KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. Frontiers in Immunology. 12. 791958–791958. 4 indexed citations
7.
Brisotto, Giulia, Elisabetta Rossi, Michela Bulfoni, et al.. (2020). Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer. Cancers. 12(4). 1005–1005. 9 indexed citations
8.
Riva, Emma, Mauro Tettamanti, Ugo Lucca, et al.. (2020). How palliative care professionals deal with predicting life expectancy at the end of life: predictors and accuracy. Supportive Care in Cancer. 29(4). 2093–2103. 5 indexed citations
9.
Pelizzari, Giacomo, Lorenzo Gerratana, Debora Basile, et al.. (2018). Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. Cancer Treatment Reviews. 72. 7–14. 21 indexed citations
10.
Spazzapan, Simon, Pierfranco Conté, Edda Simoncini, et al.. (2017). Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). Annals of Oncology. 28. vi28–vi28. 1 indexed citations
11.
Carli, Paolo, Loredana Militello, Gianmaria Miolo, et al.. (2015). Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.. PubMed. 100(6). 605–11. 2 indexed citations
12.
13.
Crivellari, Diana, Simon Spazzapan, Davide Lombardi, et al.. (2012). Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.. PubMed. 98(1). 33–8. 4 indexed citations
14.
Buti, Sebastiano, Silvia Lazzarelli, Cecilia Simonelli, et al.. (2010). Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study. Journal of Immunotherapy. 33(7). 735–741. 9 indexed citations
15.
Bearz, Alessandra, I. Garassino, Raffaele Cavina, et al.. (2007). Pemetrexed single agent in previously treated non-small cell lung cancer: A multi-institutional observational study. Lung Cancer. 60(2). 240–245. 24 indexed citations
16.
Giacalone, Annalisa, et al.. (2006). What elderly cancer patients want to know? Differences among elderly and young patients. Psycho-Oncology. 16(4). 365–370. 35 indexed citations
17.
18.
Sorio, Roberto, et al.. (2003). Ifosfamide in Advanced/Disseminated Breast Cancer. Oncology. 65(Suppl. 2). 55–58. 6 indexed citations
19.
Crivellari, Diana, Davide Lombardi, Simon Spazzapan, Andrea Veronesi, & Giuseppe Toffoli. (2003). New oral drugs in older patients: a review of idarubicin in elderly patients. Critical Reviews in Oncology/Hematology. 49(2). 153–163. 26 indexed citations
20.
Zagonel, Vittorina, Lucia Fratino, Cosimo Sacco, et al.. (1996). Reducing chemotherapy-associated toxicity in elderly cancer patients. Cancer Treatment Reviews. 22(3). 223–244. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jenny Furlanetto Breakdown of academic impact, for papers by Jacques Camerlo Breakdown of academic impact, for papers by C. Oberhoff Breakdown of academic impact, for papers by G. Schubert-Fritschle Breakdown of academic impact, for papers by Danielle Desautels Breakdown of academic impact, for papers by Cristina Falci Breakdown of academic impact, for papers by David Topolsky Breakdown of academic impact, for papers by Camille Chakiba Breakdown of academic impact, for papers by Dimitri Korol Breakdown of academic impact, for papers by Eleonora Pagan
Rankless by CCL
2026